

oncology specialty product guide

| Medication | Administration | Class of Drug | Type of Drug | Generic/ Biosimilar Available? | Manufacturer | Manufacturer Sponsored Financial Assistance? |
|---|----------------|---|---------------------------------|--------------------------------------|--------------|---|
| AFINITOR® (everolimus) | Oral | Kinase Inhibitor | Targeted Therapy | Yes | Novartis | Yes* |
| AFINITOR DISPERZ® (everolimus tablets for oral suspension) | Oral | Kinase Inhibitor | Targeted Therapy | Yes | Novartis | Yes* |
| ALECENSA® (alectinib) | Oral | Kinase Inhibitor | Targeted Therapy | No | Genentech | Yes |
| COTELLIC® (cobimetinib) | Oral | Kinase Inhibitor | Targeted Therapy | No | Genentech | Yes |
| CYCLOPHOSPHAMIDE | Oral | Alkylating Agent | Chemotherapy | | Various | No |
| ERIVEDGE® (vismodegib) | Oral | Hedgehog Pathway Inhibitor | Targeted Therapy | No | Genentech | Yes |
| FARYDAK® (panobinostat) | Oral | Histone Deacetylase Inhibitor | Chemotherapy | No | Novartis | No |
| GEFITINIB® (generic Iressa®) | Oral | Kinase Inhibitor | Targeted Therapy | | Various | No |
| GLEEVEC® (imatinib mesylate) | Oral | Kinase Inhibitor | Targeted Therapy | Yes | Novartis | Yes* |
| HERCEPTIN HYLECTA™ (trastuzumab and hyaluronidase-oysk) | Injectable | HER2/neu Receptor Antagonist | Targeted Therapy | No | Genentech | Yes |
| KISQALI® (ribociclib) | Oral | Kinase Inhibitor | Targeted Therapy | No | Novartis | Yes |
| KISQALI® FEMARA® CO-PAK (ribociclib + letrozole) | Oral | Kinase Inhibitor + Aromatase Inhibitor | Targeted + Endocrine Therapy | No | Novartis | Yes |
| LUPRON DEPOT® (leuprolide acetate for depot suspension) | Injectable | GnRH agonist | Endocrine Therapy | No | AbbVie | Yes |
| MEKINIST® (trametinib) | Oral | Kinase Inhibitor | Targeted Therapy | No | Novartis | Yes |
| NILANDRON® (nilutamide) | Oral | Anti-androgen | Endocrine Therapy | Yes | Concordia | No |

Medications listed above represent those that Meijer Specialty Pharmacy is able to dispense.

oncology specialty product guide (continued)

| Medication | Administration | Class of Drug | Type of Drug | Generic/ Biosimilar Available? | Manufacturer | Manufacturer Sponsored Financial Assistance? |
|--|----------------|--------------------------------|------------------|--------------------------------------|---------------------|---|
| NINLARO® (ixazomib) | Oral | Proteasome inhibitor | Targeted Therapy | No | Takeda | Yes |
| ODOMZO® (sonidegib) | Oral | Hedgehog pathway inhibitor | Targeted Therapy | No | Sun Pharmaceuticals | Yes |
| ONUREG® (azacitidine) | Oral | Nucleoside metabolic inhibitor | Chemotherapy | No | Celgene | Yes |
| PHEGSO™ (pertuzumab, trastuzumab and hyaluronidase-zzxf) | Injectable | HER2/neu Receptor Antagonist | Targeted Therapy | No | Genentech | Yes |
| RITUXAN HYCELA® (rituximab and hyaluronidase) | Injectable | Anti-CD20 antibody | Targeted Therapy | No | Genentech | Yes |
| ROZLYTREK® (entrectinib) | Oral | Kinase inhibitor | Targeted Therapy | No | Genentech | Yes |
| RYDAPT® (midostaurin) | Oral | Kinase inhibitor | Targeted Therapy | No | Novartis | Yes |
| SCEMBLIX® (asciminib) | Oral | Kinase inhibitor | Targeted Therapy | No | Novartis | Yes |
| SORAFENIB® (generic Nexavar®) | Oral | Kinase inhibitor | Targeted Therapy | | Various | No |
| SPRYCEL® (dasatinib) | Oral | Kinase inhibitor | Targeted Therapy | No | BMS | Yes |
| TABRECTA™ (capmatinib) | Oral | Kinase inhibitor | Targeted Therapy | No | Novartis | Yes |
| TAFINLAR® (dabrafenib) | Oral | Kinase Inhibitor | Targeted Therapy | No | Novartis | Yes |
| TARGRETIN® (bexarotene) | Oral | Retinoid | Targeted Therapy | Yes | Valeant | Yes* |
| TASIGNA® (nilotinib) | Oral | Kinase inhibitor | Targeted Therapy | No | Novartis | Yes |
| TEMODAR® (temozolomide) | Oral | Alkylating agent | Chemotherapy | Yes | Merck | No |

Medications listed above represent those that Meijer Specialty Pharmacy is able to dispense.

oncology specialty product guide (continued)

| Medication | Administration | Class of Drug | Type of Drug | Generic/ Biosimilar Available? | Manufacturer | Manufacturer Sponsored Financial Assistance? |
|---|----------------|-----------------------------------|-------------------|--------------------------------------|-------------------|---|
| TYKERB® (lapatinib) | Oral | Kinase inhibitor | Targeted Therapy | No | Novartis | Yes |
| XELODA® (capecitabine) | Oral | Nucleoside metabolic inhibitor | Chemotherapy | Yes | Genentech | No |
| YONSA® (abiraterone acetate) | Oral | Anti-androgen | Endocrine Therapy | Yes | Sun Pharma | Yes* |
| XTANDI® (enzalutamide) | Oral | Androgen receptor inhibitor | Endocrine Therapy | No | Astellas | Yes |
| ZELBORAF™ (vemurafenib) | Oral | Kinase inhibitor | Targeted Therapy | No | Genentech | Yes |
| ZOLINZA® (vorinostat) | Oral | HDAC inhibitor | Targeted Therapy | No | Merck | No |
| ZYKADIA® (ceritinib) | Oral | Kinase inhibitor | Targeted Therapy | No | Novartis | Yes |
| ZYTIGA® (abiraterone acetate) | Oral | Anti-androgen | Endocrine Therapy | Yes | Johnson & Johnson | Yes |